浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Bibliometric analysis of traditional Chinese medicines for myocardial ischemia-reperfusion injury
- ZHONGGUO YAOFANG Vol. 33, Issue 21, Pages: 2590-2596(2022)
- 作者机构：
1.广西中医药大学研究生院，南宁 530200
2.广西中医药大学第一附属医院心内科/国家中医心血管病临床医学研究中心分中心，南宁 530200
3.广西中医药大学药学院，南宁 530200
4.广西中医药大学基础医学院，南宁 530200
5.广西中医药大学博物馆，南宁 530200
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2022.21.06
CLC： R932;R-1Published：15 November 2022，
Received：30 May 2022，
Revised：05 September 2022，
扫 描 看 全 文
祁祥,卢健棋,王昱涵等.中药防治心肌缺血再灌注损伤的文献计量学分析 Δ[J].中国药房,2022,33(21):2590-2596.
QI Xiang,LU Jianqi,WANG Yuhan,et al.Bibliometric analysis of traditional Chinese medicines for myocardial ischemia-reperfusion injury[J].ZHONGGUO YAOFANG,2022,33(21):2590-2596.
祁祥,卢健棋,王昱涵等.中药防治心肌缺血再灌注损伤的文献计量学分析 Δ[J].中国药房,2022,33(21):2590-2596. DOI： 10.6039/j.issn.1001-0408.2022.21.06.
QI Xiang,LU Jianqi,WANG Yuhan,et al.Bibliometric analysis of traditional Chinese medicines for myocardial ischemia-reperfusion injury[J].ZHONGGUO YAOFANG,2022,33(21):2590-2596. DOI： 10.6039/j.issn.1001-0408.2022.21.06.
摘要
目的
2
对中药防治心肌缺血再灌注损伤（MIRI）领域的研究现状、热点进行分析，为开展相关研究提供参考依据。
方法
2
以Web of Science中收录的有关中医药治疗MIRI的文献为数据来源，进行文献计量学分析。
结果
2
本研究共计纳入972篇文献。近10年中药防治MIRI的研究呈现逐年上升趋势，2021年发表的文章被引次数最多；研究者多集中于中国；中国医学科学院北京协和医学院在该领域发文最多，并与其他机构有着较多的合作，在该领域有着较大的影响力；Sun Guibo与Sun Xiaobo是该领域高产作者，但全球作者合作并不紧密，尚未形成一定规模的合作团队；
Molecular Medicine Reports
可能是该领域最受欢迎的杂志。共被引分析发现，该领域的研究方向多集中在探索MIRI的发病机制以及找寻干预靶点方面；关键词分析显示，中药调控细胞凋亡、细胞焦亡、线粒体功能障碍、miRNA等途径改善MIRI的研究是该领域的热点，研究较多的信号通路有Nrf2通路、NF-κB通路、NLRP3炎症小体通路、TNF通路、SIRT3通路、JNK通路、PI3K/Akt通路、AMPK通路。
结论
2
近10年中药防治MIRI的研究备受关注，目前该领域的热点多集中于中药有效成分与中成药对MIRI的干预机制研究。此外，中药治疗MIRI的科研现阶段多集中于基础实验领域，建议未来多开展大规模、高质量、多中心、随机对照的临床研究，以期为中药应用于临床提供高级别循证医学证据。
Abstract
OBJECTIVE
2
To analyze the current status and research hot spots of traditional Chinese medicine （TCM） in the prevention and treatment of myocardial ischemia-reperfusion injury （MIRI）， and to provide reference for developing relevant studies.
METHODS
2
A bibliometric analysis was performed with the literature on TCM treatments for MIRI included in the Web of Science as the data source.
RESULTS
2
A total of 972 literatures were included in this study. The research on TCM for prevention and treatment of MIRI in recent 10 years showed an increasing trend year by year， and the literature published in 2021 were cited most frequently； most research scholars focused in China； Peking Union Medical College， Chinese Academy of Medical Sciences had the most papers in this field， and a lot of collaboration with other institutions， which had a large influence in the field； Sun Guibo and Sun Xiaobo were high-yielding authors in the field， but the global authorship was not very close and had not formed cooperative teams of some scale；
Molecular Medicine Reports
was perhaps the most popular journal in the field. Co-citation analysis found that the research direction in this field was mostly focused on exploring the pathogenesis of MIRI and finding intervention targets. Key words analysis revealed that TCM-regulated apoptosis， pyroptosis， mitochondrial dysfunction， miRNA and other pathways to improve MIRI research was a hot spot in the field， and more studies had focused on the Nrf2 pathway， NF-κB pathway， NLRP3 inflammasome pathway， TNF pathway， SIRT3 pathway， JNK pathway， PI3K/Akt pathway and AMPK pathway.
CONCLUSIONS
2
Much attention has been paid to the prevention and treatment of MIRI by TCM in the past 10 years， and the current hot spots in this field are mostly focused on the studies about the intervention mechanism of TCM’s active ingredients and Chinese patent medicines on MIRI. Moreover， the research about TCM in the treatment of MIRI is mostly focused on the field of basic experiments at present， and it is recommended that many large-scale， high-quality， multicenter， randomized controlled clinical studies should be carried out in the future， to provide high-grade evidence-based evidence for the application of TCM in clinic.
关键词
中药心肌缺血再灌注损伤心血管疾病文献计量学
Keywords
myocardial ischemia-reperfusion injurycardiovascular diseasebibliometrics
references
MEIER T，GRÄFE K，SENN F，et al. Cardiovascular mortality attributable to dietary risk factors in 51 countries in the WHO European Region from 1990 to 2016：a syste- matic analysis of the global burden of disease study[J]. Eur J Epidemiol，2019，34（1）：37-55.
HEUSCH G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective[J]. Nat Rev Cardiol，2020，17（12）：773-789.
HAUSENLOY D J，KHARBANDA R K，MØLLER U K，et al. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction （CONDI-2/ERIC-PPCI）：a single-blind randomised controlled trial[J]. Lancet，2019，394（10207）：1415-1424.
岳栋芳,李永芳.中药及其复方抗心肌缺血再灌注损伤的作用机制研究进展[J/OL].中药药理与临床，2022：1-25[2022-10-19]. https：//kns.cnki.net/kcms/detail/detail.aspx?dbcode=CAPJ&dbname=CAPJLAST&filename=ZYYL-20220311000&uniplatform=NZKPT&v=g3PdBwCvGt-CRvqgc-7x52COLo55F5YCBHn8k4U0PTWIdJdgYLX- N5ct0aGLjbSUs5.DOI：10.13412/j.cnki.zyyl.20220313.003https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CAPJ&dbname=CAPJLAST&filename=ZYYL-20220311000&uniplatform=NZKPT&v=g3PdBwCvGt-CRvqgc-7x52COLo55F5YCBHn8k4U0PTWIdJdgYLX-N5ct0aGLjbSUs5.DOI:10.13412/j.cnki.zyyl.20220313.003.
MA D，YANG B，GUAN B Y，et al. A bibliometric analysis of pyroptosis from 2001 to 2021[J]. Front Immunol，2021，12：731933.
祁祥，卢健棋，朱智德，等.近10年经方真武汤的文献计量学研究与可视化分析[J/OL].中国现代中药，2022：1-14[2022-09-04]. https：//kns.cnki.net/kcms/detail/detail.aspx?dbcode=CAPJ&dbname=CAPJLAST&filename=YJXX20220126001&uniplatform=NZKPT&v=GhfZblymhfFgbpjnxjRHK1Si4Vu1Evty0PgolzqEsRP9x7nkQr AtKdhQX-JUD0W3.DOI：10.13313/j.issn.1673-4890.20211014001https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CAPJ&dbname=CAPJLAST&filename=YJXX20220126001&uniplatform=NZKPT&v=GhfZblymhfFgbpjnxjRHK1Si4Vu1Evty0PgolzqEsRP9x7nkQrAtKdhQX-JUD0W3.DOI:10.13313/j.issn.1673-4890.20211014001.
LI Q，SHEN L，WANG Z，et al. Tanshinone ⅡA protects against myocardial ischemia reperfusion injury by activa- ting the PI3K/Akt/mTOR signaling pathway[J]. Biome- decine Pharmacother，2016，84：106-114.
ZHUO Y Q，YUAN R，CHEN X X，et al. Tanshinone I exerts cardiovascular protective effects in vivo and in vitro through inhibiting necroptosis via Akt/Nrf2 signaling pathway[J]. Chin Med，2021，16（1）：48.
JIANG L J，YIN X J，CHEN Y H，et al. Proteomic analysis reveals ginsenoside Rb1 attenuates myocardial ischemia/reperfusion injury through inhibiting ROS production from mitochondrial complex Ⅰ[J]. Theranostics，2021，11（4）：1703-1720.
LI L，PAN C S，YAN L，et al. Ginsenoside Rg1 ameliorates rat myocardial ischemia-reperfusion injury by modulating energy metabolism pathways[J]. Front Physiol，2018，9：78.
LI L，WANG Y L，GUO R，et al. Ginsenoside Rg3-loaded，reactive oxygen species-responsive polymeric nanoparticles for alleviating myocardial ischemia-reperfusion injury[J]. J Control Release，2020，317：259-272.
XUE Y，FU W W，LIU Y Z，et al. Ginsenoside Rb2 alle- viates myocardial ischemia/reperfusion injury in rats through SIRT1 activation[J]. J Food Sci，2020，85（11）：4039-4049.
YIN B，HOU X W，LU M L. Astragaloside Ⅳ attenuates myocardial ischemia/reperfusion injury in rats via inhibition of calcium-sensing receptor-mediated apoptotic signaling pathways[J]. Acta Pharmacol Sin，2019，40（5）：599-607.
YU L M，LI Z，DONG X，et al. Polydatin protects diabetic heart against ischemia-reperfusion injury via Notch1/Hes1-mediated activation of pten/Akt signaling[J]. Oxid Med Cell Longev，2018，2018：2750695.
HU Y J，PAN H W，PENG J Q，et al. Resveratrol inhibits necroptosis by mediating the TNF-α/RIP1/RIP3/MLKL pathway in myocardial hypoxia/reoxygenation injury[J]. Acta Biochim Biophys Sin （Shanghai），2021，53（4）：430-437.
ZHAO G L，YU L M，GAO W L，et al. Berberine protects rat heart from ischemia/reperfusion injury via activating JAK2/STAT3 signaling and attenuating endoplasmic reticulum stress[J]. Acta Pharmacol Sin，2016，37（3）：354-367.
JIN Z，GAN C，LUO G，et al. Notoginsenoside R1 protects hypoxia-reoxygenation deprivation-induced injury by upregulation of miR-132 in H9c2 cells[J]. Hum Exp Toxicol，2021，40（12_suppl）：S29-S38.
CHANG X Y，ZHANG K，ZHOU R，et al. Cardioprotective effects of salidroside on myocardial ischemia-reperfusion injury in coronary artery occlusion-induced rats and Langendorff-perfused rat hearts[J]. Int J Cardiol，2016，215：532-544.
BAI J N，WANG Q C，QI J X，et al. Promoting effect of baicalin on nitric oxide production in CMECs via activa- ting the PI3K-AKT-ENOS pathway attenuates myocardial ischemia-reperfusion injury[J]. Phytomedicine，2019，63：153035.
MA H E，HAO J P，LIU H H，et al. Peoniflorin preconditioning protects against myocardial ischemia/reperfusion injury through inhibiting myocardial apoptosis：risk pathway involved[J]. Appl Biochem Biotechnol，2022，194（3）：1149-1165.
WANG R Y，WANG M，ZHOU J H，et al. Calenduloside E suppresses calcium overload by promoting the interaction between L-type calcium channels and Bcl2-associated athanogene 3 to alleviate myocardial ischemia/reperfusion injury[J]. J Adv Res，2021，34：173-186.
WANG S M，YE L F，WANG L H. Protective mechanism of Shenmai on myocardial ischemia-reperfusion through the energy metabolism pathway[J]. Am J Transl Res，2019，11（7）：4046-4062.
WANG R Y，WANG M，ZHOU J H，et al. Shuxuening injection protects against myocardial ischemia-reperfusion injury through reducing oxidative stress，inflammation and thrombosis[J]. Ann Transl Med，2019，7（20）：562.
ZHANG L，WANG Y，LI C，et al. Dan Hong injection protects against cardiomyocytes apoptosis by maintaining mitochondrial integrity through Keap1/nuclear factor erythroid 2-related factor 2/JNK pathway[J]. Front Pharmacol，2020，11：591197.
CHEN J R，WEI J，WANG L Y，et al. Cardioprotection against ischemia/reperfusion injury by Qishenyiqi pill® via ameliorate of multiple mitochondrial dysfunctions[J]. Drug Des Devel Ther，2015，9：3051-3066.
LI F，ZHENG X J，FAN X X，et al. Yiqifumai powder injection attenuates ischemia/reperfusion-induced myocardial apoptosis through AMPK activation[J]. Rejuvenation Res，2016，19（6）：495-508.
AL-SALAM S，HASHMI S. Myocardial ischemia reperfusion injury：apoptotic，inflammatory and oxidative stress role of galectin-3[J]. Cell Physiol Biochem，2018，50（3）：1123-1139.
ZHANG Y，WEI L，SUN D，et al. Tanshinone ⅡA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats[J]. Diabetes Obes Metab，2010，12（4）：316-322.
王秋静，王泺璎，王苹，等.红景天苷对心肌缺血再灌注损伤大鼠心肌的保护作用[J].中成药，2021，43（11）：3147-3151.
SHI J J，GAO W Q，SHAO F. Pyroptosis：gasdermin-mediated programmed necrotic cell death[J]. Trends Biochem Sci，2017，42（4）：245-254.
栾飞，彭利霞，雷紫琴，等. NLRP3炎症小体介导的细胞焦亡与心肌缺血再灌注损伤的关系及中医药干预策略[J].中药药理与临床，2022，38（4）：216-228.
XU L J，CHEN R C，MA X Y，et al. Scutellarin protects against myocardial ischemia-reperfusion injury by suppressing NLRP3 inflammasome activation[J]. Phytomedicine，2020，68：153169.
韦亚忠，薛晓梅，何斌.活性氧介导心肌缺血再灌注损伤的研究进展[J].上海交通大学学报（医学版），2021，41（6）：826-829.
YANG L，ZHANG Y，ZHU M M，et al. Resveratrol attenuates myocardial ischemia/reperfusion injury through up-regulation of vascular endothelial growth factor B[J]. Free Radic Biol Med，2016，101：1-9.
周曼丽，俞赟丰，冯宇，等.线粒体质量控制体系介导心肌缺血再灌注损伤的治疗策略[J].中草药，2021，52（20）：6381-6390.
CARBONELL T，GOMES A V. microRNAs in the regulation of cellular redox status and its implications in myocardial ischemia-reperfusion injury[J]. Redox Biol，2020，36：101607.
YE Y M，HU Z Y，LIN Y，et al. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury[J]. Cardiovasc Res，2010，87（3）：535-544.
WANG L L，CHEN X Q，WANG Y C，et al. miR-30c-5p mediates the effects of Panax notoginseng saponins in myocardial ischemia reperfusion injury by inhibiting oxidative stress-induced cell damage[J]. Biomedecine Pharmacother，2020，125：109963.
0
Views
3
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.